scispace - formally typeset
D

Darrin P. Smith

Researcher at University of Cambridge

Publications -  25
Citations -  4108

Darrin P. Smith is an academic researcher from University of Cambridge. The author has contributed to research in topics: RET proto-oncogene & Receptor tyrosine kinase. The author has an hindex of 21, co-authored 25 publications receiving 4027 citations. Previous affiliations of Darrin P. Smith include The Breast Cancer Research Foundation.

Papers
More filters
Journal ArticleDOI

Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

TL;DR: A degenerate peptide library is used to show that each of nine tyrosine kinases investigated has a unique optimal peptide substrate, and indicates that a point mutation in the RET receptor-type tyosine kinase, which causes multiple endocrine neoplasia type 2B, results in a shift in peptide substrates specificity.
Journal ArticleDOI

GDNF signalling through the Ret receptor tyrosine kinase

TL;DR: It is shown that glial-cell-line-derived neurotrophic factor (GDNF)7, a distant member of the transforming growth factor(TGF)-β superfamily, signals through the Ret RTK, and that GDNF, in addition to its potential role in the differentiation and survival of central nervous system neurons8–12, has profound effects on kidney organogenesis and the development of the peripheral nervous system.
Journal ArticleDOI

Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours

TL;DR: A missense mutation, resulting in the substitution of a threonine for a methionine at codon 918 in the tyrosine kinase catalytic domain, is reported in the germline of 26 of 28 apparently distinct families with MEN 2B.
Journal Article

A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC

TL;DR: A missense mutation in the intracellular tyrosine kinase domain of RET is reported in the germline of a family with FMTC that does not have a cysteine codon mutation, confirming that it is likely to be of pathological significance rather than a rare polymorphism.
Journal ArticleDOI

Prolonged survival of pig orthotopic heart grafts treated with cyclosporin a

TL;DR: Cyclosporin A was given to pigs receiving orthotopic cardiac allografts from donors mismatched at the major locus and median survival is greater than 68 days, with 4 animals still alive.